Aristides Capital LLC Has $4.59 Million Stake in Eton Pharmaceuticals, Inc. $ETON

Aristides Capital LLC raised its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 15.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 186,041 shares of the company’s stock after buying an additional 24,605 shares during the quarter. Eton Pharmaceuticals comprises about 0.8% of Aristides Capital LLC’s portfolio, making the stock its 20th largest position. Aristides Capital LLC’s holdings in Eton Pharmaceuticals were worth $4,591,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in ETON. Quarry LP bought a new position in shares of Eton Pharmaceuticals in the 3rd quarter valued at $37,000. Legal & General Group Plc bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter worth $41,000. Caitong International Asset Management Co. Ltd acquired a new position in Eton Pharmaceuticals during the fourth quarter worth about $44,000. China Universal Asset Management Co. Ltd. acquired a new position in Eton Pharmaceuticals during the fourth quarter worth about $74,000. Finally, SG Americas Securities LLC bought a new position in shares of Eton Pharmaceuticals in the fourth quarter worth about $109,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ETON has been the topic of a number of research analyst reports. HC Wainwright raised their price target on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Zacks Research downgraded shares of Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen raised Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. Finally, Canaccord Genuity Group assumed coverage on Eton Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating and a $60.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Eton Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $45.75.

Eton Pharmaceuticals Trading Up 1.3%

NASDAQ:ETON opened at $44.14 on Friday. Eton Pharmaceuticals, Inc. has a 52 week low of $13.78 and a 52 week high of $44.91. The firm’s fifty day moving average is $34.43 and its 200-day moving average is $25.31. The firm has a market cap of $1.21 billion, a P/E ratio of -630.48 and a beta of 0.86. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.88 and a current ratio of 1.21.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Thursday, May 14th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). The firm had revenue of $24.27 million for the quarter, compared to the consensus estimate of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. Equities analysts expect that Eton Pharmaceuticals, Inc. will post 0.75 earnings per share for the current year.

Insider Transactions at Eton Pharmaceuticals

In related news, Director Jennifer Mckie Adams sold 50,000 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the transaction, the director directly owned 50,000 shares of the company’s stock, valued at $1,624,000. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Krempa sold 42,797 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the completion of the sale, the insider owned 25,249 shares of the company’s stock, valued at $843,064.11. The trade was a 62.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 150,000 shares of company stock worth $4,853,921 over the last three months. 16.49% of the stock is owned by company insiders.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.